Disclosed positions

Estimated from their latest filings — positions may have changed since

$9.00M

combined est. value

Stock	Shares	Price	Value	Weight	As of
RCUSArcus Biosciences, Inc.	224,024	$28.92	$6.48M	72%	2026-01-23
SNDXSyndax Pharmaceuticals Inc	114,000	$22.08	$2.52M	28%	2026-02-04

RCUS

Arcus Biosciences, Inc.

$6.48M

224,024 sh

SNDX

Syndax Pharmaceuticals Inc

$2.52M

114,000 sh

All filings on record

Every Form 4 transaction we track for this filer

all 10buys 0sells 5

Stock	Transaction	Date	~6mo later
SNDXSyndax Pharmaceuticals Inc	Grant — · 24,000 sh	2026-02-04	—
RCUSArcus Biosciences, Inc.	Grant — · 31,000 sh	2026-01-23	—
RCUSArcus Biosciences, Inc.	Sell $221.2K · 9,983 sh	2025-12-17	—
RCUSArcus Biosciences, Inc.	Sell $245.7K · 11,225 sh	2025-12-16	—
RCUSArcus Biosciences, Inc.	Sell $954.1K · 50,291 sh	2025-11-07	—
RCUSArcus Biosciences, Inc.	Exercise $61.7K · 50,291 sh	2025-11-07	—
RCUSArcus Biosciences, Inc.	Sell $568.6K · 37,792 sh	2025-10-08	—
RCUSArcus Biosciences, Inc.	Exercise $46.4K · 37,792 sh	2025-10-08	—
RCUSArcus Biosciences, Inc.	Sell $181.8K · 12,500 sh	2025-10-06	—
RCUSArcus Biosciences, Inc.	Exercise $15.3K · 12,500 sh	2025-10-06	—

SNDXGrant

2026-02-04 · Syndax Pharmaceuticals Inc

24,000

—

RCUSGrant

2026-01-23 · Arcus Biosciences, Inc.

31,000

—

RCUSSell

2025-12-17 · Arcus Biosciences, Inc.

$221.2K

—

RCUSSell

2025-12-16 · Arcus Biosciences, Inc.

$245.7K

—

RCUSSell

2025-11-07 · Arcus Biosciences, Inc.

$954.1K

—

RCUSExercise

2025-11-07 · Arcus Biosciences, Inc.

$61.7K

—

RCUSSell

2025-10-08 · Arcus Biosciences, Inc.

$568.6K

—

RCUSExercise

2025-10-08 · Arcus Biosciences, Inc.

$46.4K

—

RCUSSell

2025-10-06 · Arcus Biosciences, Inc.

$181.8K

—

RCUSExercise

2025-10-06 · Arcus Biosciences, Inc.

$15.3K

—

Outcomes measure each disclosed buy against the closing price ~6 months (120 trading days) later, with the S&P 500 over the same span for context. Pre-scheduled 10b5-1 plan trades are excluded from the record. Positions are estimated from the latest reported post-transaction holdings, split-adjusted, at the latest close. Built from SEC Form 4 filings and market prices — past outcomes, not predictions or advice.